By combining with vascular injury agents, Vadimezan, the targeting efficiency of PDL1‐conjugated platelets at 4T1 lung metastatic tumor sites can be increased by three and ten times, respectively, compared with single PDL1‐conjugated platelets and free aPD‐L1. This evidence concerns the gene CD274 and metastatic neoplasm.